Abstract
New psychoactive substances (NPS) have drastically modified the world drug scene. Synthetic or substituted cathinones (SCs), a popular class of NPS, are β-keto amphetamine analogues. These drugs are also known as legal highs, research chemicals, bath salts, plant food, or glass cleaner, and labeled «not for human use» or «not tested for hazards or toxicity» . However, there is a lack of epidemiological data concerning the SCs. Several factors have contributed to their increasing popularity, including their falsely legal image, their more reasonable costs, and their distribution based on the new technologies. SCs are mainly used for their stimulant properties, often serving as a replacement for others illicit stimulant drugs. The psychoactive and sympathomimetic effects of these drugs resemble those of amphetamine, methamphetamine, ecstasy, and cocaine, albeit to varying degrees. Clinical effects of SCs are individual-, dose- and route of administration-dependent. The primary effects sought by the users include euphoria, empathy, increased sexual performance, and increased sociability. Recent reports on abuse of novel synthetic cathinone derivatives call attention to the serious physical and psychological risks resulting from their consumption, thereby emphasizing the growing use of these drugs might constitute an important public health issue. Acute toxicity is the leading cause of SCs-induced fatalities . Users report a number of negative physical and psychiatric effects associated with SCs use. Cardiac, psychiatric, and neurological adverse effects are the most common reported ones requiring medical care. SCs use may also lead to violence, homicidal combative behavior, self-mutilation, coma, and death.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aarde SM, Creehan KM, Vandewater SA et al (2015) In vivo potency and efficacy of the novel cathinone alpha-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology 232(16):3045–3055. https://doi.org/10.1007/s00213-015-3944-8
Adamowicz P, Gil D, Skulska A, Tokarczyk B (2013) Analysis of MDPV in blood—determination and interpretation. J Anal Toxicol 37(5):308–312. https://doi.org/10.1093/jat/bkt025
AIDES/Sidaction/AMG/Inserm (2013) SLAM, première enquête qualitative en France. Février 2013. https://issuu.com/ministere-sante/docs/rapport_morlat_2013_mise_en_ligne
Andrabi S, Greene S, Moukaddam N, Li B (2015) New drugs of abuse and withdrawal syndromes. Emerg Med Clin North Am 33(4):779–795. https://doi.org/10.1016/j.emc.2015.07.006
Baumann MH, Bukhari MO, Lehner KR et al (2017) Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs. Curr Top Behav Neurosci 32:93–117. https://doi.org/10.1007/7854_2016_53
Boehringer Ingelheim G (1967) Pyrrolidino ketones. Unit 3314970 A
Cheong JH, Choi MJ, Jang CG et al (2017) Behavioral evidence for the abuse potential of the novel synthetic cathinone alpha-pyrrolidinopentiothiophenone (PVT) in rodents. Psychopharmacology 234(5):857–867. https://doi.org/10.1007/s00213-017-4526-8
Cottencin O, Rolland B, Karila L (2014) New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des 20(25):4106–4111
DEA (2017) Schedules of controlled substances: placement of 10 synthetic cathinones into schedule I. https://www.federalregister.gov/documents/2017/03/01/2017-03974/schedules-of-controlled-substances-placement-of-10-synthetic-cathinones-into-schedule-i. Accessed May 2017
EMCDDA (2014a) European monitoring centre for drugs and drug addiction. European drug report 2014: trends and developments. Publications Office of the European Union 2014, Luxembourg, 80 pp
EMCDDA (2014b) EMCDDA–Europol joint report on a new psychoactive substance: MDPV (3,4-methylenedioxypyrovalerone). Publications Office of the European Union, Luxembourg
EMCDDA (2014c) Perspectives on drugs. Injection of synthetic cathinones. http://www.emcdda.europa.eu/topics/pods/synthetic-cathinones-injection_en. Accessed 5 May 2014
EMCDDA (2017) European drug report 2017: trends and developments. Publications Office of the European Union, Luxembourg
Emerson T, Cisek J (1993) Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med 22:1897–1903
Erowid (a) http://www.erowid.org/chemicals/methylone/methylone_info1.shtml. Accessed July 2010
Erowid (b) Methylone addictive potential. https://www.erowid.org/experiences/exp.php?ID=27823
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2010) Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone). http://www.emcdda.europa.eu/system/files/publications/559/2010_Mephedrone_Joint_report_279
Gannon BM, Rice KC, Collins GT (2017) Reinforcing effects of abused ‘bath salts’ constituents 3,4-methylenedioxypyrovalerone and alpha-pyrrolidinopentiophenone and their enantiomers. Behav Pharmacol 28(7):578–581. https://doi.org/10.1097/FBP.00000000000003152017
Glennon RA, Young R (2016) Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinovalerophenone (α-PVP). Brain Res Bull 126(Pt 1):111–126. https://doi.org/10.1016/j.brainresbull.2016.04.011
Griffiths P, Lopez D, Sedefov R et al (2010) Khat use and monitoring drug use in Europe: the current situation and issues for the future. J Ethnopharmacol 132(3):578–583. https://doi.org/10.1016/j.jep.2010.04.046
Info.sheet: Naphyrone. http://crew2000.org.uk. Accessed 8 Nov 2012
Jacob P, Shulgin A (1996) Inventors, Neurobiological Technologies, Inc., assignee. Preparation of novel N-substituted-2-amino-3′,4′-methylenedioxypropiophenones as anti-depressant and anti-parkinsonism agents. US Patent WO9639133, 6 June 1996
Journal Officiel (2012) Arrêté du 27 juillet 2012 modifiant les arrêtés du 22 février 1990 fixant la liste des substances classées comme stupéfiants et la liste des substances psychotropes. https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000026246525&categorieLien=id. Accessed 8 March 2016
Karila L, Reynaud M (2010) Mephedrone: a designer drug legally available on the Web. Presse Med 39(7–8):834–835
Karila L, Reynaud M (2011) GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 3(9):552–559. https://doi.org/10.1002/dta.210
Karila L, Megarbane B, Cottencin O, Lejoyeux M (2015) Synthetic cathinones: a new public health problem. Curr Neuropharmacol 13(1):12–20. https://doi.org/10.2174/1570159X13666141210224137
Karila L, Lafaye G, Scocard A et al (2017) MDPV and alpha-PVP use in humans: the twisted sisters. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.10.007
Krikorian AD (1984) Kat and its use: an historical perspective. J Ethnopharmacol 12(2):115–178
Marusich JA, Antonazzo KR, Wiley JL et al (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206–213. https://doi.org/10.1016/j.neuropharm.2014.02.016
Marusich JA, Lefever TW, Blough BE et al (2016) Pharmacological effects of methamphetamine and alpha-PVP vapor and injection. Neurotoxicology 55:83–91. https://doi.org/10.1016/j.neuro.2016.05.015
Meltzer P, Butler D, Deschamps J, Madras B (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49(4):1420–1432. https://doi.org/10.1021/jm050797a
Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397(3):1225–1233. https://doi.org/10.1007/s00216-010-3636-5
Morris H (2010) Mephedrone: the phantom menace. Vice:98–100
Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8(1):33–42. https://doi.org/10.1007/s13181-011-0193-z
Psychoactive Substances Act (2016). http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted. Accessed 29 May 2016
Randolph SA (2014) Synthetic drugs: bath salts and spice. Workplace Health Saf 62(2):88
Rosenbaum CD, Carreiro SP, Babu KM (2012) Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 8(1):15–32. https://doi.org/10.1007/s13181-011-0202-2
Sanchez S (1929) Sur un homologue de l’ephedrine. Bull Soc Chim Fr 45:284–286
Schifano F, Albanese A, Fergus S et al (2011) Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacology 214(3):593–602. https://doi.org/10.1007/s00213-010-2070-x
Schifano F, Corkery J, Ghodse A (2012) Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom. J Clin Psychopharmacol 32:710–714. https://doi.org/10.1097/JCP.0b013e318266c70c
Shimizu E, Watanabe H, Kojima T et al (2007) Combined intoxication with methylone and 5-MeO-MIPT. Prog Neuropsychopharmacol Biol Psychiatry 31(1):288–291
Stanciu CN, Penders TM, Gnanasegaram SA et al (2017) The behavioral profile of methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (PVP)—A systematic review. Curr Drug Abuse Rev. https://doi.org/10.2174/1874473710666170321122226
Thomae K (1963) α-Pyrrolidinoketones, patent specification 933507
United Nations Office on Drugs and Crime (UNODC) (2015) Decision 58/12—Inclusion of 3,4-methylenedioxypyrovalerone (MDPV) in Schedule II of the Convention on Psychotropic Substances of 1971.74. https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_58/2015_Desicions/Desicion_58_12.pdf
UNODC (2016) World drug report 2016. United Nations Publication, Sales No. E.16.XI.7
Wander A (1963) α-Pyrrolidinovalerophenones, patent specification 927475
Weaver MF, Hopper JA, Gunderson EW (2015) Designer drugs 2015: assessment and management. Addict Sci Clin Pract 10:8. https://doi.org/10.1186/s13722-015-0024-7
Weinstein AM, Rosca P, Fattore L, London ED (2017) Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry 8:156. https://doi.org/10.3389/fpsyt.2017.00156
WHO (2014) Methylone (bk‐MDMA)—critical review report—expert committee on drug dependence thirty‐sixth meeting—Geneva, 16–20 June 2014
Winder GS, Stern N, Hosanagar A (2013) Are “bath salts” the next generation of stimulant abuse? J Subst Abuse Treat 44(1):42–45. https://doi.org/10.1016/j.jsat.2012.02.003
Wood D, Hunter L, Measham F, Dargan P (2012) Limited use of novel psychoactive substances in South London nightclubs. QJM 105:959–964
Zawilska JB, Wojcieszak J (2013) Designer cathinones—an emerging class of novel recreational drugs. Forensic Sci Int 231(1–3):425–453. https://doi.org/10.1016/j.forsciint.2013.04.015
Zawilska J, Wojcieszak J (2017) α-Pyrrolidinophenones: a new wave of designer cathinones. Forensic Toxicol 35(2):201–216. https://doi.org/10.1007/s11419-016-0353-6
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Karila, L., Benyamina, A. (2018). The Effects and Risks Associated with Synthetic Cathinones Use in Humans. In: Zawilska, J. (eds) Synthetic Cathinones. Current Topics in Neurotoxicity, vol 12. Springer, Cham. https://doi.org/10.1007/978-3-319-78707-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-78707-7_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78706-0
Online ISBN: 978-3-319-78707-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)